-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.Börse Börse FrankfurtSymbol SG7-
SAGE TherapeuticsBörse Börse FrankfurtSymbol SG7
-
SAGE TherapeuticsBörse Börse BerlinSymbol SG7
-
SAGE TherapeuticsBörse Börse StuttgartSymbol SG7
-
SAGE TherapeuticsBörse Börse MünchenSymbol SG7
-
SAGE THERAPEUTICS INCBörse Börse DüsseldorfSymbol SG7
-
SAGE THERAPEUTICS INCBörse Quotrix System der Börse DüsseldorfSymbol SG7
-
SAGE THERAPEUTICS INCBörse Gettex System der Börse MünchenSymbol SG7
-
SAGE THERAPEUTICS INCBörse Tradegate System der Deutsche Börse AG (60%)Symbol SG7
-
Sage Therapeutics, Inc.Börse NasdaqISIN US78667J1088Symbol SAGE
-
ISIN US78667J1088 WKN: A117WFSymbol SAGE
-
SAGE Therapeutics outperformed den DAX um +67 % vom 24.07.2014 bis 12.07.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 77,31 USD -0,60%
Entdecke die 6 ETFs in denen SAGE Therapeutics am höchsten gewichtet ist Insgesamt in 9 ETFs enthalten
Dir gefallen die Informationen zu SAGE Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu SAGE Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Dir gefallen die Informationen zu SAGE Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Dir gefallen die Informationen zu SAGE Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
27 News & Informationen zur SAGE Therapeutics Aktie
Sage Therapeutics Inc (SAGE) Q2 2021 Earnings Call Transcript
SAGE earnings call for the period ending June 30, 2021.
SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q2 2021 Results – Earnings Call Transcript
SAGE Therapeutics, Inc. (NASDAQ:SAGE) Q2 2021 Earnings Conference Call August 03, 2021, 08:00 ET Company Participants Jeff Boyle – Investor Contact Barry Greene – President, CEO &…
Sage Therapeutics, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:SAGE)
The following slide deck was published by Sage Therapeutics, Inc.
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Lags Revenue Estimates
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -8.28% and -19.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
(NASDAQ:SAGE)Sage Therapeutics shares rise on narrower Q2 net loss, cash position update
Sage Therapeutics (SAGE) shares rise more than 8% during premarket trading after the company reported a narrower second-quarter net loss and provided a cash position update.The…
Sage Therapeutics EPS misses by $0.15, misses on revenue (NASDAQ:SAGE)
Sage Therapeutics (SAGE): Q2 GAAP EPS of -$1.83 misses by $0.15.Revenue of $1.64M (+50.5% Y/Y) misses by $0.37M.Continued pipeline expansion and acceleration advancing all three…
Were Hedge Funds Right About Ormat Technologies, Inc. (ORA)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However…
Sage Therapeutics: Showing Upside, But There Are Plenty of Unknowns (NASDAQ:SAGE)
With $2 billion in cash from a debatable Biogen deal, multiple data readouts in 2021, and insider buying after the recent readout-driven sell off, SAGE stock merits a deeper dive.
Do Hedge Funds Love Schneider National, Inc. (SNDR)?
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually…
Where Do Hedge Funds Stand On Workiva Inc (WK)?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred…
Hedge Funds Are Dumping Sunnova Energy International Inc. (NOVA)
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900…
Hedge Funds Aren’t Crazy About SAGE Therapeutics Inc (SAGE) Anymore
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However…
Sage Therapeutics Needs To Show Improved Data (NASDAQ:SAGE)
While there is good potential upside for Sage Therapeutics with positive data, there is also substantial downside if their depression franchise falters.
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Several drugmakers have important clinical trial updates on the way.
Sage Therapeutics : to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
Sage Therapeutics, Inc. , a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today… | July 8, 2021
Sage Therapeutics To Participate In Cowen's Psychedelics & Novel Mechanisms In Neuropsychiatry Summit
Sage Therapeutics, Inc. SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Hedge Funds Are Dumping Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
In this article we are going to use hedge fund sentiment as a tool and determine whether Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is a…
Sage Therapeutics To Participate In SVB Leerink's 3rd Annual CNS Forum
Sage Therapeutics, Inc. SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with
Hedge Funds Have Never Been This Bullish On Everbridge, Inc. (EVBG)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings…
What Happened to Sage Therapeutics Stock?
Sage has been struggling for some time to bring its flagship antidepressant to the market.
Stocks That Hit 52-Week Highs On Friday
This morning 150 companies reached new 52-week highs.
Interesting Points: Eli Lilly (NYSE:LLY) was the largest firm by market cap to set a new …
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 14) 10X …
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ja…
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 12) …
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 7) …
FT Health: Priorities for 2021
FT writers and readers identify global challenges and WHO chief outlines case for investing in public health
Largest global study of ‘long Covid’ finds many patients unable to return to work six months later
Recent studies have shown a growing number of patients with Covid-19 experience persistent symptoms.